Abstract
IntroductionLiving in an area with no or deficient structures for trans health care is disadvantageous for trans people. By providing an internet-based health care programme, i²TransHealth aims at reducing structural disadvantages for trans people living in areas lacking specialised care. The e-health intervention consists of video consultations and a 1:1 chat with a study therapist. Additionally, the i²TransHealth network cooperates with physicians, who especially offer crisis intervention close to the participants’ place of residence. The aim of this study is to evaluate the (cost-)effectiveness of the internet-based health care programme for trans people compared with a control (waiting) group. The following research questions will be examined with a sample of 163 trans people: Does a 4-month treatment with the i²TransHealth internet-based health care programme improve patient-reported health-outcomes? Is i²TransHealth cost-effective compared with standard care from a societal or health care payers’ perspective? Does the participation in and support by i²TransHealth lead to an increase of trans-related expertise in the physician network?Methods and analysisIn a randomised controlled trial, the outcomes of an internet-based health care programme for trans people will be investigated. In the intervention group, participants are invited to use i²TransHealth for 4 months. Participants allocated to the control group will be able to start with their transition-related care after 4 months of study participation. The primary outcome measure is defined as the reduction of psychosomatic symptoms, as assessed by the Brief Symptom Inventory-18, 4 months after using the i²TransHealth programme. Participants in both groups will undergo an assessment at baseline and 4 months after using i²TransHealth.Ethics and disseminationPositive ethical approval was obtained from the Hamburg Medical Association (PV7131). The results will be disseminated to service users and their families via media, to health care professionals via professional training and meetings and to researchers via conferences and publications.Trial registration numberNCT04290286.Protocol version22 December 2021 (V.1.0)
Funder
Innovation Funds of the Joint Federal Committee (G-BA), Germany
Reference66 articles.
1. European Society for Sexual Medicine Position Statement "Assessment and Hormonal Management in Adolescent and Adult Trans People, With Attention for Sexual Function and Satisfaction";T'Sjoen;J Sex Med,2020
2. Council of the European Union . Council Recommendation of 8 June 2009 on an action in the field of rare diseases. Off J Eur Union, 2009 C 151/02 2009;C 151/02:4, 2009.
3. Institute of Medicine (US) Committee on the Health Professions Education Summit . Health professions education: a bridge to quality. Washington (DC: National Academies Press (US), 2003. http://www.ncbi.nlm.nih.gov/books/NBK221528/
4. National Action League for People with Rare Diseases . National plan of action for people with rare diseases. Bonn 2013.
5. Hormonal therapy and sex reassignment: a systematic review and meta-analysis of quality of life and psychosocial outcomes
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献